Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C: A long term follow-up study after histologic diagnosis

Cancer

Volumn 89, Issue 1, 2000, Pages 53-59

  Aizawa, Yoshio ^a   Shibamoto, Yuka ^a   Takagi, Ichiro ^a   Zeniya, Mikio ^a   Toda, Gotaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Hepatocellular carcinoma; Interferon; Liver biopsy

Indexed keywords

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER STAGING; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ALCOHOL DRINKING; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034234726     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.0.CO;2-6     Document Type: Article

References (30)

1. Takano S, Yokosuka Y, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21;650-5.
2. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
3. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nagano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by the detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
4. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between B- and C-viral infection in Japan. Hepatology 1995;22:1027-33.
5. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer MC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized, control trial. N Engl J Med 1989;321:1501-6.
6. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
7. Horiike N, Fujisawa T, Michikata K, Tada K, Masumoto T, Iuchi H, et al. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep 1998;5:1171-4.
8. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic-active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
9. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24: 141-7.
10. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
12. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351: 1773-7.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
14. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:248-75.
15. Peto R, Pike MC. Conservatism of the approximation (O-E)/E in the logrank test for survival data on tumor incidence data. Biometrics 1973;29:579-84.
16. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12: 680-7.
17. Chiba T. Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996;31:552-8.
18. Silini E, Botteli R, Asti M, Bruno S, Candusso ME, Brambilia S, et al. Hepatitis C virus genotype and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199-205.
19. Bruno S, Silini E, Crosignani A, Borzio E, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
20. Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angels County, California. Hepatology 1997;25:226-8.
21. Benvegnu L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 1996;41: 49S-55S.
22. Sato A. Kato Y, Nakata K, Nakao K, Daikoku M, Ishii N, et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus-and hepatitis C virus-associated cirrhosis. J Gastroenterol Hepatol 1996;11:944-8.
23. Haydon GH, Jarvis LM, Simmonds P, Harrison DJ, Garden OJ, Hayes PC. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut 1997;40:128-32.
24. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
25. Fukuda R, Ishimura R, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-7.
26. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999;86:793-8.
27. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995;22:135-42.
28. Ide T, Sata M, Suzuki H, Murashima S, Miyajima I, Sirachi M, et al. Evaluation of interferon treatment in cirrhotic patients with hepatitis C. J Jpn A Infect Dis 1996;70:597-604.
29. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Tsubota A, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30.
30. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113:558-66.